Online inquiry

IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8978MR)

This product GTTS-WQ8978MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL22 gene. The antibody can be applied in Inflammatory conditions research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_020525.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 50616
UniProt ID Q9GZX6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ8978MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12932MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PankoMab
GTTS-WQ3413MR IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA aALB03
GTTS-WQ13049MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ13781MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-1033
GTTS-WQ14908MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ10210MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LDP-02
GTTS-WQ15483MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA UCB-0107
GTTS-WQ15168MR IVTScrip™ mRNA-Anti-CD6, T1h(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA T1h
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW